Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025)

Innate Pharma has reported Cash & Equivalents for 9 years, with the latest figure at $32.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 53.91% year-over-year to $32.7 million; the trailing twelve-month figure through Dec 2025 stood at $32.7 million (down 53.91% YoY), and the FY2025 full-year result was $32.7 million, down 53.91% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $32.7 million, down from $60.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $164.7 million in Q2 2021, with the low at $32.7 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $88.8 million across 5 years, with a median of $81.0 million in 2024.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 99.87% — and 2024, when it fell 6.6%.
• Innate Pharma's Cash & Equivalents stood at $118.7 million in 2021, then dropped by 27.6% to $85.9 million in 2022, then decreased by 11.59% to $76.0 million in 2023, then decreased by 6.6% to $71.0 million in 2024, then plunged by 53.91% to $32.7 million in 2025.
• The last three Cash & Equivalents figures came in at $32.7 million (Q4 2025), $60.8 million (Q2 2025), and $71.0 million (Q4 2024), per Business Quant data.